Corbus Pharmaceuticals Holdings, Inc. CRBP
Set alert
As of Nov 2, 3:52 PM ET
- YTD
- -51.72%
- 1 year
- -67.65%
- Open
- 4.22
- Prev close
- 4.22
- Mkt cap
- 75.91M
- Vol
- 555.90K
- Avg vol
- 931.02K
- EPS
- -6.11
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.90
- High
- 4.23
- Forward P/E
- -2.51
- Beta
- 2.56
- Short ratio
- 8.28
- Inst. own
- 105.21%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 16.87
- 200-d avg
- 37.65
- 1y target
- 56.78
News
1 week ago defenseworld.net
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock Now Rated “Moderate Buy” by Wall Street Analysts
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight analysts that are presently covering the company,…
-
1 week ago benzinga.com
Corbus Pharmaceuticals To Present Late Breaking Data From CRB-913 Canyon-1 Phase 1B Study At Obesity Week 2026
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data from the CRB-913 Canyon-1 Phase…
1 week ago globenewswire.com
Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
NORWOOD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that…
1 month ago globenewswire.com
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
Incidence and prevalence of OPSCC continue to rise in the U.S. largely driven by HPV infection OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L+ setting in the U.S. with…
1 month ago zacks.com
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?
Corbus Pharmaceuticals' positive obesity data boosts its cannabinoid strategy, while CRB-701 and cash needs add key context for investors.
1 month ago marketbeat.com
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study
Corbus Pharmaceuticals NASDAQ: CRBP reported top-line results from CANYON-1, a Phase 1b trial evaluating CRB-913, an oral, peripherally restricted CB1 inverse agonist for obesity. The 12-week,…
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $35 price target.
1 month ago benzinga.com
Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'
Clinical-stage biopharmaceutical firm Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) on Monday reported topline results from its CANYON-1 Phase 1b trial evaluating CRB-913 as an obesity…
1 month ago benzinga.com
Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'
Corbus Pharmaceuticals reports positive Phase 1b trial results for obesity drug CRB-913, demonstrating significant 12-week weight loss.
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics…
-
1 month ago benzinga.com
Market-Moving News for September 14th
GLW: -8% | Corning shares are trading lower after the company announced a $2 billion offering. ELMT: 49% | Elmet Group Lands $450M US Government Investment To Expand Tungsten Manufacturing, To Invest…
-
1 month ago benzinga.com
Corbus Pharma Announces Topline Data From CANYON-1 Phase 1b Trial Of CRB-913 Demonstrating Statistically Significant And Clinically Meaningful Weight Loss In Obesity
CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed CRB-913 was generally well tolerated with psychiatric…
1 month ago globenewswire.com
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed CRB-913 was generally well tolerated with psychiatric…
1 month ago benzinga.com
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals
-
1 month ago benzinga.com
Corbus Pharmaceuticals To Report Topline CANYON-1 Obesity Trial Data For CRB-913; Management Team Will Host A Conference Call Webcast On Monday, September 14 At 8:00 a.m. EDT
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing new therapies in oncology and obesity, today announced that the Company’s management team will host…
1 month ago globenewswire.com
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT
2 months ago globenewswire.com
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NORWOOD, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the…
-
2 months ago benzinga.com
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $52 to $48.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and lowers the price target from $40 to $35.
-
2 months ago benzinga.com
Corbus Pharmaceuticals Q2 EPS $(1.81) Misses $(1.26) Estimate
Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(1.26) by 43.65 percent. This is a 25.69 percent decrease over…
-
3 months ago benzinga.com
Corbus Pharmaceuticals' Last Participant Completes Last Clinical Visit In Its CANYON-1 Phase 1b Clinical Study Of CRB-913 To Treat Obesity
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the last patient has completed their last clinical…
3 months ago globenewswire.com
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
Dose-finding Phase 1b study (n=240) on track for topline data in September 2026 CANYON-1 follows promising data from Phase 1a SAD/MAD study that demonstrated differentiated GI tolerability from GLP-1…
3 months ago globenewswire.com
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
Company expects to initiate enrollment in TEMPO-1 in September 2026 OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000…
3 months ago globenewswire.com
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new…
-
4 months ago benzinga.com
Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34
Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $44 to $34.
-
4 months ago benzinga.com
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $52
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $54 to $52.
4 months ago marketbeat.com
Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near
Corbus Pharmaceuticals NASDAQ: CRBP Chief Executive Yuval Cohen outlined the company's near-term clinical readout schedule and development plans for its two lead drug candidates during a Jefferies…
5 months ago seekingalpha.com
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript
5 months ago marketbeat.com
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study
Corbus Pharmaceuticals NASDAQ: CRBP executives and oncology specialists used an ASCO-linked discussion to outline the rationale for focusing the company's CRB-701 program on recurrent or metastatic…
-
5 months ago benzinga.com
Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $30
Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $38 to $30.
5 months ago seekingalpha.com
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $40 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $40 price target.
-
5 months ago benzinga.com
Corbus Pharma Reports Updated Data From Phase 1/2 Clinical Study Of CRB-701, Next-Gen Nectin-4 Targeted Antibody Drug Conjugate
Data affirms Corbus strategy of targeting tumor types with elevated Nectin-4 expression and clear unmet medical needs while providing an attractive commercial path forwardConfirmed ORR of 42.9%…
5 months ago globenewswire.com
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
NORWOOD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today reported updated data from its Phase 1/2 clinical study…
-
5 months ago benzinga.com
Mizuho Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $44
Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target from $40 to $44.
5 months ago marketbeat.com
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout
Corbus Pharmaceuticals NASDAQ: CRBP Chief Executive Officer Yuval Cohen said investors should expect more mature clinical updates for CRB-701 at the upcoming ASCO meeting, including the first…
-
5 months ago benzinga.com
Corbus Pharmaceuticals To Discuss Updated Data For Its Phase 1/2 Trial Of CRB-701 Antibody Drug Candidate To Treat Head And Neck Squamous Cell Carcinoma
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that the Company's management team…
5 months ago globenewswire.com
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity,…
5 months ago globenewswire.com
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity,…
-
5 months ago benzinga.com
Jefferies Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $33
Jefferies analyst Maury Raycroft maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and lowers the price target from $36 to $33.
-
5 months ago benzinga.com
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $54
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $57 to $54.
-
5 months ago benzinga.com
Guggenheim Reiterates Buy on Corbus Pharmaceuticals, Maintains $45 Price Target
Guggenheim analyst Paul Jeng reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $45 price target.
-
5 months ago benzinga.com
Corbus Pharmaceuticals Q1 EPS $(1.23) Misses $(1.22) Estimate
Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(1.22) by 0.82 percent. This is a 11.51 percent increase over…
-
6 months ago benzinga.com
Guggenheim Initiates Coverage On Corbus Pharmaceuticals with Buy Rating, Announces Price Target of $45
Guggenheim analyst Paul Jeng initiates coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy rating and announces Price Target of $45.
-
6 months ago benzinga.com
Corbus Pharmaceuticals Doses Last Participant In Its CANYON-1 Phase 1b Clinical Study Of CRB-913 To Treat Obesity
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced the last patient has been enrolled and…
6 months ago benzinga.com
Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge
Corbus reports FDA alignment on the CRB-701 path, as analysts flag upside tied to the head and neck cancer opportunity and obesity pipeline.
-
6 months ago benzinga.com
Corbus Secures FDA Alignment On CRB-701 Registrational Studies For HNSCC And Cervical Cancer; Updated Phase 1/2 Data Set For ASCO 2026
FDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to support potential accelerated approval in second-line HNSCC and cervical cancer Updated CRB-701…
-
7 months ago benzinga.com
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $57
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target from $53 to $57.